CX-546 is the company code given for an ampakine compound by its developer, Cortex Pharmaceuticals. This compound comes right at the heels of cx-516, another ampakine compound that showed much promise as a treatment for ADHD during animal trials, but proved to be disappointing when it was tested on humans. This time around, the studies […]

CX-614 is the company code given to an ampakine research chemical developed by Cortex Pharmaceuticals. It is the third type of ampakine released by the pharmaceutical company right after cx-516 and cx-546. CX614 has been the subject of numerous clinical studies that are exploring its potential as treatment for neurological disorders such as Alzheimer’s disease […]

CX-717 is the company code given to the ampakine developed by Cortex Pharmaceuticals. It is the most recent and perhaps the most promising of all the ampakines developed by the pharmaceutical company. The cx-717 is the fourth ampakine to come from Cortex after cx-516, cx-546, and cx-614. This ampakine has so far shown very strong […]

S-18986 is the designated company code given to investigational new drug compound developed by Servier, one of the leading pharmaceutical companies to come out of France. The drug is categorized as an ampakine, a positive allosteric modulator of AMPA glutamate receptors. AMPA, which is short for α- Amino-3-hydroxy-5- methylisoxazole-4- propionic acid, are receptors that are […]

IDRA-21 is yet another obscure compound that is being investigated for its cognitive enhancing properties. This compound has intrigued a good portion of the nootropic community owing to its potency, which initial lab tests have shown to be at least 10 to much as 30 times more powerful than aniracetam. IDRA-21 is an ampakine compound […]